Can stem cells fix blood problems after CAR-T? early trial launches

NCT ID NCT07212335

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether stem cells from donated umbilical cord blood can safely help people whose blood counts stay dangerously low after CAR-T therapy. The trial will enroll 15 adults with leukemia, lymphoma, or myeloma. Participants receive weekly stem cell infusions for up to 4 weeks, and researchers will monitor side effects and whether blood cell levels improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord blood-derived mesenchymal stem cells
What this could lead to: If it works, this could offer a new way to help patients recover normal blood cell counts after CAR-T therapy, reducing the need for transfusions.
What could go wrong: This is a very early, small trial (15 people) with no control group. The stem cells may not improve blood counts, and there could be side effects like infusion reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Cytopenia lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY

Contacts and locations

Locations

Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
RECRUITING

Tianjin, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.